Teva (TEVA) Continues Early Weakness Following FY12 Outlook
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (Nasdaq: TEVA) continues to slump Wednesday, following guidance for fiscal 2012 which saw earnings and revenues at the low-end of consensus expectations.
Teva sees FY12 sales of $22 billion and non-GAAP EPS of $5.48 to $5.68, versus revs of $21.97 billion and EPS of $5.67 expected on the Street. Although the top-end of earnings beat views, the median calls for something below expectations.
Click here for more color.
Teva sees FY12 sales of $22 billion and non-GAAP EPS of $5.48 to $5.68, versus revs of $21.97 billion and EPS of $5.67 expected on the Street. Although the top-end of earnings beat views, the median calls for something below expectations.
Click here for more color.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Vireo Growth completes acquisition of C21 Investments
- S&P 500 may pull back before midterms, but Citi says buy the dip
Create E-mail Alert Related Categories
Insiders' BlogRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
